Literature DB >> 15809480

Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer.

Jong-Ho Kim1, Johannes Czernin, Martin S Allen-Auerbach, Benjamin S Halpern, Barbara J Fueger, Joel R Hecht, Osman Ratib, Michael E Phelps, Wolfgang A Weber.   

Abstract

UNLABELLED: The aim of this study was to compare PET with (18)F-FDG PET, in-line PET/CT, and software fusion of independently acquired CT and PET scans for staging of recurrent colorectal cancer (CRC).
METHODS: Fifty-one patients with suspected recurrent CRC were studied with in-line PET/CT. Thirty-four of these patients underwent an additional CT scan of the chest or abdomen within 4 wk of PET/CT. Software fusion of PET and CT was performed using a fully automated, intensity-based algorithm. The accuracy of the coregistration of PET and CT scans was evaluated by measuring the distance between landmarks visible in the PET and CT images. Histologic evaluation and follow-up for 6 mo served as the gold standard for the presence or absence of recurrent CRC.
RESULTS: On a patient basis, the accuracy of staging was significantly higher for in-line PET/CT than for PET (88% vs. 71%, P = 0.01). Software fusion of the independently acquired PET and CT images was unsuccessful in 8 patients (24%). In the remaining patients, the mean distance between 62 landmarks visible in PET and CT was 12.9 +/- 7.9 mm, whereas it was only 7.7 +/- 4.7 mm for in-line PET/CT (P < 0.001).
CONCLUSION: In patients with suspected recurrent CRC, in-line PET/CT significantly improves staging compared with PET alone. Due to its high failure rate, software fusion of independently acquired PET and CT studies cannot be considered to represent an alternative to in-line PET/CT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809480

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

1.  The role of FDG-PET/CT in the detection of recurrent colorectal cancer.

Authors:  Jana Votrubova; Otakar Belohlavek; Monika Jaruskova; Martin Oliverius; Radka Lohynska; Kristina Trskova; Eva Sedlackova; Ludmila Lipska; Vladimira Stahalova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-25       Impact factor: 9.236

2.  Software-based fusion of PET and CT images for suspected recurrent lung cancer.

Authors:  Yuji Nakamoto; Michio Senda; Tomohisa Okada; Setsu Sakamoto; Tsuneo Saga; Tatsuya Higashi; Kaori Togashi
Journal:  Mol Imaging Biol       Date:  2008-02-22       Impact factor: 3.488

Review 3.  Multimodality image registration with software: state-of-the-art.

Authors:  Piotr J Slomka; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

4.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

5.  PET-CT enteroclysis: a new technique for evaluation of inflammatory diseases of the intestine.

Authors:  Chandan Jyoti Das; Govind Makharia; Rakesh Kumar; Madhavi Chawla; Pooja Goswami; Raju Sharma; Arun Malhotra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-21       Impact factor: 9.236

6.  Role of PET/CT in the detection of liver metastases from colorectal cancer.

Authors:  A Orlacchio; O Schillaci; N Fusco; P Broccoli; M Maurici; M Yamgoue; R Danieli; S D'Urso; G Simonetti
Journal:  Radiol Med       Date:  2009-05-14       Impact factor: 3.469

7.  The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI.

Authors:  G Kong; C Jackson; D M Koh; V Lewington; B Sharma; G Brown; D Cunningham; G J R Cook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-18       Impact factor: 9.236

8.  Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.

Authors:  Nan-Jing Peng; Chin Hu; Tai-Ming King; Yu-Li Chiu; Jui-Ho Wang; Ren-Shyan Liu
Journal:  Cancer Biother Radiopharm       Date:  2013-05-28       Impact factor: 3.099

Review 9.  PET/CT in oncology: for which tumours is it the reference standard?

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

Review 10.  Colorectal cancer: imaging surveillance following resection of primary tumour.

Authors:  Ken Miles; Guy Burkill
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.